Skip to content
Catalyst

Astragalus membranaceusFinding

Astragalus membranaceus increases clinical effective rate (composite responder rate)

raisesModerate evidenceFinding

01 · The sentence it was drawn from

“During the treatment period, the total effective rate of the astragalus-RAAS blocker combination group was markedly higher than that of the RAAS blocker group (odds ratio [OR] = 3.63, 95% CI [2.59, 5.09], p < 0.00001; Figure 2).”
Quoted verbatim from Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis.
This finding among the 2 findings on its endpoint

Astragalus membranaceus

Clinical effective rate (composite responder rate)

raises

Effect as reported

3.63odds ratio

CI 2.59 to 5.09

Who
Adults with stage III diabetic nephropathy (Mogensen staging); 14 pooled Chinese trials in which both arms received the same ACE inhibitor or ARB and only one arm also received astragalus; routes pooled (injection and oral herb)
Dose studied
Pooled; astragalus injection 20 to 60 mL per day or oral astragalus 20 to 180 g per day, added to an ACE inhibitor or ARB, 1 to 48 weeks

Moderate evidencePMID 38836372 · 2024

02 · The study

Study
meta-analysis
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Renal failure
What else it reported2 findings · 0 compounds · 2 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M704C1XT7TE7W13HBW00Y7QX